Drugmaker Eli Lilly (NYSE: LLY) hasn't been exempt from the recent market pullback, but its stock shot higher following the ...

Zack D Films is back at it again, but this time, he's included a gross scene at the end of his clip to highlight Ozempic side ...

Eli Lilly's Mounjaro (Tirzepatide), a dual GIP and GLP-1 receptor agonist, has launched in India, generating buzz as a weight ...

A once-weekly dose of tirzepatide (Mounjaro) can lead to significant, sustained weight loss for up to 3 years in adults with ...

Lilly's announcement that it would make its experimental weight-loss pill in the U.S. comes amid administration pressure on ...

As GLP-1s quiet the constant hum of hunger, are they a permanent pharmaceutical crutch, or can they create space to let us ...

Shares of Novo Nordisk, the Danish pharmaceutical company behind weight-loss drugs Ozempic and Wegovy, plummeted this week.

Drug manufacturer Eli Lilly announced this week that an encouraging clinical trial of their new pill promises a convenient, ...

Eli Lilly & Co.'s stock soared 14% Thursday, to put it on track for its biggest one-day gain in about 25 years, after the drugmaker reported positive results from a late-stage trial of a GLP-1 ...

A new pill designed to help with weight loss and blood sugar control is showing promise in early studies. Eli Lilly said its ...

A new drug, called orforglipron, can help people with diabetes manage their A1C and weight, according to topline results from ...

As CMS maintains limits on GLP-1 coverage for weight loss, new efficacy data and shifting prescribing patterns point to sustained high demand across the drug class. Here are four updates: 1. Federal ...